Overdose of atypical antipsychotics: Clinical presentation, mechanisms of toxicity and management

CNS Drugs

Volumn 26, Issue 7, 2012, Pages 601-611

  Levine, Michael ^a,b   Ruha, Anne Michelle ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

Author keywords

Antipsychotic; atypical antipsychotic; overdose; toxicity

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; HISTAMINE H1 RECEPTOR; ILOPERIDONE; LURASIDONE; MUSCARINIC M1 RECEPTOR; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; ZIPRASIDONE;

CENTRAL NERVOUS SYSTEM DEPRESSION; DRUG DISTRIBUTION; DRUG OVERDOSE; DRUG PROTEIN BINDING; HUMAN; HYPOTENSION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; STANDING; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICOKINETICS;

ANTIPSYCHOTIC AGENTS; DISEASE MANAGEMENT; HUMANS; OVERDOSE; SCHIZOPHRENIA;

EID: 84862557732     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11631640-000000000-00000     Document Type: Review

References (95)

1. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004; 18: 877-93 (Pubitemid 39612017)
2. Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. Clin Toxicol 2001; 39: 1-14 (Pubitemid 32332271)
3. Meltzer HY, Li Z, Kaneda Y, et al. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1159-72 (Pubitemid 37464960)
4. Moller HJ. Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodlogical issues and clinical consequences. World J Biol Psychiatry 2000; 1: 75-91
5. Ross CA, Margolis RL, Reading SA, et al. Neurobiology of schizophrenia. Neuron 2006; 52: 139-53 (Pubitemid 44466356)
6. Raggi MA, Mandrioli R, Sabbioni C, et al. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring, and pharmacological interactions. Curr Med Chem 2004; 11: 279-96 (Pubitemid 38240208)
7. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011; 11: 59-67
8. Meyer JM. Pharmacotherapy of psychosis and mania. In: Brunton LL, editor. Goodman and Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw Hill, 2011; 417-55
9. 1A receptor activity. J Pharmacol Exp Ther 2010; 334: 171-81
10. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998; 32: 215-8
11. Blin O. A comparative review of new antipsychotics. Can J Psychiatry 1999; 44: 235-44 (Pubitemid 29237060)
12. Cheslik TA, Erramouspe J. Extrapyramidal symptoms following accidental ingestion of risperidone in a child. Ann Pharmacother 1996; 30: 360-3 (Pubitemid 26107691)
13. Richelson E.Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60 Suppl. 10: 5-14 (Pubitemid 29237170)
14. Borison RL. Recent advances in the pharmacotherapy of schizophrenia. Harvard Rev Psychiatry 1997; 4: 255-71 (Pubitemid 27086601)
15. Hoiberg MP, Nielsen B. Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients. Nord J Psychiatry 2006; 60: 207-12 (Pubitemid 43832468)
16. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21: 911-36 (Pubitemid 47557106)
17. Levine M, Brooks DE, Truitt CA, et al. Toxicology in the ICU, part 1: general overview and approach to treatment. Chest 2011; 140: 795-806
18. Grace AA, Bunney BS, Moore H, et al. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 1997; 20: 31-7 (Pubitemid 26421230)
19. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153: 466-76 (Pubitemid 26113309)
20. Solian prescribing information [online]. Available from URL: http://www.sanofi.com.au/products/aus-pi-solian.pdf [Accessed 2012 Jan 30]
21. Merck and Co., Inc. Saphris prescribing information [online]. Available from URL: http://www.spfiles.com/pisaphrisv1.pdf [Accessed 2012 Jan 30]
22. Bristol Myers-Squibb. Aripiprazole prescribing information [online]. Available from URL: http://www.abilify.com/pdf/pi.aspx [Accessed 2012 Jan 30]
23. Novartis Pharmaceuticals Corporation. Clozapine prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/ Clozaril.pdf [Accessed 2012 Jan 30]
24. Arif SA,MitchellMM. Iloperidone: a new drug for the treatment of schizophrenia. Am J Health Syst Pharm 2011; 68: 301-8
25. Sunovion Pharmaceuticals Inc. Lurasidone prescribing information [online]. Available from URL: http://www.latuda.com/ LatudaPrescribingInformation.pdf [Accessed 2012 Jan 30]
26. Astra Zenica. Quetiapine prescribing information [online]. Available from URL: http://www1.astrazeneca-us.com/pi/Seroquel.pdf [Accessed 2012 Jan 30]
27. Janssen Pharmaceuticals Inc. Risperidone prescribing information [online]. Available from URL: http://www.risperdal.com/prescribing.html [Accessed 2012 Jan 30]
28. Lilly USA LLC. Olanzapine prescribing Information [online]. Available from URL: http://pi.lilly.com/us/zyprexapi.pdf [Accessed 2012 Jan 30]
29. Janssen Pharmaceuticals Inc. Paliperidone prescribing information [online]. Available from URL: http://www.invega.com/prescribing-information [Accessed 2012 Jan 30]
30. Pfizer Inc. Ziprasidone prescribing information [online]. Available from URL: http://labeling.pfizer.com/ShowLabeling.aspx?id=584 [Accessed 2012 Jan 30]
31. Keck Jr PE, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry 2002; 63 Suppl. 4: 3-11 (Pubitemid 34242105)
32. Yang PL, Plosker GL. Paliperidone extended release. CNS Drugs 2007; 21: 417-25 (Pubitemid 46698504)
33. Dubois D. Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer. Curr Opin Pediatr 2005; 17: 227-33
34. Wadworth AN, Heel RC. Remoxipride: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia. Drugs 1990; 40: 863-79 (Pubitemid 120032435)
35. Wiesel FA, Alfredsson G, Ehrnebo M, et al. The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol 1980; 17: 385-91 (Pubitemid 10117852)
36. Rosenzweig P, Canal M, Patat A, et al. A review of the pharmacokinetics, tolerability, and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol 2002; 17: 1-13 (Pubitemid 34130349)
37. Micromedex. Version 2.0 [online]. Available from URL: http://www.thomsonhc.com/micromedex2/librarian [Accessed 2011 Oct 17]
38. Bronstein AC, Spyker DA, Cantilena Jr LR, et al. 2010 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th annual report. Clin Toxicol (Phila) 2011; 49: 910-41
39. Isbister GK, Balit CR, Kilham HA. Antipsychotic poisoning in young children: a systematic review. Drug Saf 2005; 28: 1029-44 (Pubitemid 41483707)
40. Balit CR, Isbister GK, Hackett LP, et al. Quetiapine poisoning: a case series. Ann Emerg Med 2003; 42: 751-8 (Pubitemid 37486794)
41. Gresham C, Ruha AM. Respiratory failure following isolated ziprasidone ingestion in a toddler. J Med Toxicol 2010; 6: 41-3
42. O'Malley GF, Seifert S, Heard K, et al. Olanzapine overdose mimicking opioid intoxication. Ann Emerg Med 1999; 34: 279-81 (Pubitemid 29361880)
43. Palenzona S, Meier PK, Kupferschmidt H, et al. The clinical picture of olanzapine poisoning with special reference to fluctuating mental status. J Toxicol Clin Toxicol 2004; 42: 27-32 (Pubitemid 38450935)
44. Page CB, Calver LA, Isbister GK. Risperidone overdose causes extrapyramidal effects but not cardiac toxicity. J Clin Psychopharmacol 2010; 30: 387-90
45. Lapid MI, Cunningham JL, Hugo Z, et al. Acute dystonia associated with paliperidone overdose. Psychosomatics 2011; 52: 291-4
46. Theisen FM, Grabarkiewicz J, Fegbeutel C, et al. Olanzapine overdose in children and adolescents: two case reports and a review of the literature. J Child Adolesc Psychopharmacol 2005; 15: 986-95 (Pubitemid 43042990)
47. Cohen LG, Fatalo A, Thompson BT, et al. Olanzapine overdose with serum concentrations. Ann Emerg Med 1999; 34: 275-8 (Pubitemid 29361879)
48. Khan KH, Tham TC. Neuroleptic malignant syndrome induced by quetiapine overdose. Br J Hosp Med (Lond) 2008; 69: 171
49. Isbister GK, Balit CR, Macleod D, et al. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. J Clin Psychopharmacol 2010; 30: 391-5
50. Zareba W, Lin DA. Antipsychotic drugs and QT interval prolongation. Psychiatr Q 2003; 74: 291-306 (Pubitemid 38115323)
51. Tan HH, Hoppe J, Heard K. A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. Am J Emerg Med 2009; 27: 607-16
52. Moller HJ. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1101-11
53. Green B. Focus on amisulpride. Curr Med Res Opin 2002; 18: 113-7 (Pubitemid 34665747)
54. Isbister GK, Murray L, John S, et al. Amisulpride deliberate self-poisoning causing severe cardiac toxicity include QT prolongation and torsades de pointes. Med J Aust 2006; 184: 354-6
55. Joy JP, Coulter CV, Duffull SB, et al. Prediction of torsades de pointes from the QT interval: analysis of a case series of amisulpride overdoses. Clin Pharmacol Ther 2011; 90: 243-5
56. Wang YC, Yang CC, Bai YM, et al. Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine. Neuropsychobiology 2008; 57: 200-5
57. Tracqui A, Mutter-Schmidt C, Kintz P, et al. Amisulpride poisoning: a report on two cases. Hum Exp Toxicol 1995; 14: 294-8
58. Ventimiglia J, Kalali AH, Citrome L. A review of new atypical antipsychotic launches in the United States. Psychiatry (Edgemeont) 2010; 7: 13-5
59. Weber J, McCormack PL. Asenapine. CNS Drugs 2009; 23: 781-92
60. Balaraman R, Gandhi H. Asenapine, a new sublingual atypical antipsychotic. J Pharmacol Pharmacother 2010; 1: 60-1
61. Lofton AL, Klein-Schwartz W. Atypical experience: a case series of pediatric aripiprazole exposures. Clin Toxicol (Phila) 2005; 43: 151-3
62. Young MC, Shah N, Cantrell FL, et al. Risk assessment of isolated aripiprazole exposures and toxicities: a retrospective study. Clin Toxicol 2009; 47: 580-3
63. Seifert SA, Schwartz MD, Thomas JD. Aripiprazole (abilify) overdose in a child. Clin Toxicol (Phila) 2005; 43: 193-5
64. Melhem S, Katz K, Jameson A. Prolonged toxicity in a 2-year-old after accidental ingestion of aripiprazole. Pediatr Emerg Care 2009; 25: 105-6
65. Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QT interval. Expert Opin Pharmacother 2002; 3: 479-98 (Pubitemid 34520859)
66. Hippius H. A historical prospective of clozapine. J Clin Psychiatry 1999; 60 Suppl 12: 22-3
67. Reith D, Montelone JP, Whyte IM, et al. Features and toxicokinetics of clozapine in overdose. Ther Drug Monit 1998; 20: 92-7 (Pubitemid 28110109)
68. Bird AM, Smith TL, Walton AE. Current treatment strategies for clozapine-induced sialorrhea. Ann Pharmacother 2011; 45: 667-75
69. Thomas L, Pollak PT. Delayed recovery associated with persistent serum concentrations after clozapine overdose. J Emerg Med 2003; 25: 61-6 (Pubitemid 36829167)
70. Warner B, Hoffmann P. Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug React Toxicol Rev 2002; 21: 189-203 (Pubitemid 36018766)
71. Layland JJ, Liew D, Prior DL. Clozapine-induced cardiotoxicity: a clinical update. Med J Aust 2009; 190: 190-2
72. Meeker JE, Herrmann PW, Som CW. Clozapine tissue concentrations following an apparent suicidal overdose of clozaril. J Anal Toxicol 1992; 16: 54-6
73. Scott LJ. Ioperidone in schizophrenia. CNS Drugs 2009; 23: 867-80
74. 1A receptors. Life Sci 2003; 73: 1151-9
75. Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses 2011; 4: 251-7
76. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011; 65: 189-210
77. Morgan M, Hackett LP, Isbister GK. Olanzapine overdose: a case series of analytically confirmed cases. Int Clin Psychopharmacol 2007; 22: 183-6 (Pubitemid 46559876)
78. Waring WS, Wrate J, Bateman DN. Olanzapine overdose is associated with acute muscle injury. Hum Exp Toxicol 2006; 25: 735-40 (Pubitemid 46101700)
79. Tse GH, Warner MH, Waring WS. Prolonged toxicity after massive olanzapine overdose: two cases with confirmatory laboratory data. J Toxicol Sci 2008; 33: 363-5
80. Ngo A, Ciranni M, Olson KR. Acute quetiapine overdose in adults: a 5-year retrospective case series. Ann Emerg Med 2008; 52: 541-7
81. Isbister GK, Duffull SB. Quetiapine overdose: predicting intubation, duration of ventilation, cardiac monitoring, and the effect of activated charcoal. Int Clin Psychopharmacol 2009; 24: 174-80
82. Hunfeld NG, Westerman EM, Boswijk DJ, et al. Quetiapine in overdosage: A clinical and pharmacokinetic analysis of 14 cases. Ther Drug Monit 2006; 28: 185-9 (Pubitemid 44314947)
83. Bodmer M, Burkard T, Kummer O, et al. Pharmacokinetics and pharmacodynamics of quetiapine in a patient with a massive overdose. Ther Drug Monit 2008; 30: 553-6
84. de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010; 51: 80-8
85. Levine M, LoVecchio F, Tafoya P, et al. Paliperidone overdose with delayed onset of toxicity. Ann Emerg Med 2011; 58: 80-2
86. LoVecchio F, Watts D, Eckholdt P. Three-year experience with ziprasidone exposures. Am J Emerg Med 2005; 23: 586-7
87. Klein-Schwartz W, Lofton AL, Benson BE, et al. Prospective observational multi-poison center study of ziprasidone exposures. Clin Toxicol 2007; 45: 782-6 (Pubitemid 350208859)
88. Alipour A, Cruz R, Lott RS. Torsades de pointes after ziprasidone overdose with coingestants. J Clin Psychopharmacol 2010; 30: 76-7
89. Manini AF, Raspberry D, Hoffman RS, et al. QT prolongation and torsadess de pointes following overdose of ziprasidone and amantadine. J Med Toxicol 2007; 3: 178-81
90. Gupta A, Lawrence AT, Krishnan K, et al. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsades de pointes. Am Heart J 2007; 153: 891-9 (Pubitemid 46809861)
91. White CM, Xie J, Chow MS, et al. Prophylactic magnesium to decrease the arrhythmogenic potential of class III antiarrhythmic agents in a rabbit model. Pharmacotherapy 1999; 19: 635-40 (Pubitemid 29211809)
92. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003; 89: 1363-72 (Pubitemid 37311108)
93. Rhyee SH, Pedapati EV, Thompson J. Prolonged delirium after quetiapine overdose. Pediatr Emerg Care 2010; 26: 754-6
94. Sartorius A, Hewer W, Zink M, et al. High-dose clozapine intoxication. J Clin Psychopharmacol 2002; 22: 91-2
95. Howland MA. Antidotes in Depth (A12): Physostigmine Salicylate. In: Howland MA, editor. Goldfrank's Toxicologic Emergencies. 9th ed. New York: McGraw-Hill, 2011